by rdbiomed | Mar 8, 2018 | Company News
Professor Peter Dettmar has been working on reflux since 1981 and is a world-leading expert on using the stomach enzyme pepsin as a marker for the disease. In his former role as global R&D Director of Gastrointestinals for Reckitt Benckiser Healthcare, Professor...
by rdbiomed | Dec 21, 2017 | Company News, reflux
Peptest has been used to evaluate the success of laparoscopic fundoplication surgery for the treatment of reflux disease in a new research study. Laparoscopic fundoplication surgery is when the top part of the stomach is wrapped around the lower part of the oesophagus...
by rdbiomed | Dec 6, 2017 | Company News, reflux
Researchers in Italy have used Peptest to investigate whether the stomach enzyme pepsin causes worsening of symptoms for patients with chronic cough and chronic respiratory disease. As part of the study at Sacro Cuore-Don Calabria Hospital in Verona, 42 patients were...
by rdbiomed | Dec 4, 2017 | Company News
Maxhealth Medical Group, Peptest’s Chinese distributor, has presented the non-invasive device for diagnosing reflux to key opinion leaders at a China conference in November. The China Healthcare International Association, Gastroesophageal Reflux and Multidisciplinary...
by rdbiomed | Nov 13, 2017 | Company News
We’re pleased to announce that we have achieved the highly-coveted ISO 13485: 2016 certification. ISO 13485 is an internationally agreed standard specific to the medical devices industry. To achieve ISO 13485 certification, RD Biomed – the Hull-based medical...
by rdbiomed | Oct 27, 2017 | Company News
A three-month study into how Peptest can be used to diagnose gastro-oesophageal reflux disease has begun in China, following an official launch in August. The launch took place at the ‘Normal range reference of Chinese PGI research conference’ on 12 August 2017 at the...
Recent Comments